Scarica l'app Stockscreener
2.50
2.72%
-0.07
Dopo l'orario di chiusura:
2.40
-0.10
-4.00%
Serina Therapeutics Inc Borsa (SER) Ultime notizie
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Serina Therapeutics will present its neurological disease work Sept. 14. - Stock Titan
Serina Therapeutics Announces Independent Committee Recommends Advance of SER-252 Parkinson’s Study to Cohort 2 - Quiver Quantitative
Some Parkinson’s patients showed sustained motor improvement in Serina’s study - Stock Titan
Serina Therapeutics (SER) Dips 2.40% to $2.44, Testing Key Support at $2.32Block Trade Flow - vinanet.vn
Serina Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Serina Therapeutics Establishes Flexible Equity Financing Agreement - The Globe and Mail
Serina Therapeutics Secures $25 Million Equity Financing Facility with Roth Principal - Minichart
Serina Therapeutics Sets Up $25 Million Equity Purchase Facility With Roth Principal Investments - TradingView
IPO Databook: Serina Therapeutics (SER US)Aug 2026 - Smartkarma
Serina TherapeuticsOffers Up To 12,500,000 Shares Of Common Stock By Roth Principal InvestmentsSEC Filing - TradingView
BTIG Maintains Serina Therapeutics(SER.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Serina Therapeutics, Inc. announced that it expects to receive $25 million in funding from Roth Principal Investments, LLC - marketscreener.com
Serina (SER) Move: Ends Lower by 1.53% at $2.58 in the Latest Reading; Next Session: the Near-Term Reference Band Stretches From $2.45 to $2.71 in the Available RecordSwing Entry Signals - vinanet.vn
Serina Therapeutics Q2 loss widens to $(0.55) as revenue drops to zero - scanx.trade
Serina Therapeutics Completes Dosing for 8 Parkinson’s Patients - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SER Q1 2026 Earnings: Wider Loss Falls Short of Estimates Despite Modest Share GainEarnings Trend Analysis - vinanet.vn
Serina Therapeutics Inc (SER) Stock News Today - TradingKey
Serina Therapeutics (SER) Holds Steady Above $2.24 Support, Up 0.43% in Measured SessionDelta Hedging - vinanet.vn
Serina Therapeutics (SER) Advances 5.83% to $2.18, Approaching Key Resistance at $2.29McClellan Summation - dars.gov.et
SER Q1 2026 Earnings: Wider-than-Expected Loss of -$0.58 per Share Signals Rising Pipeline CostsEarnings Call Highlights - vinanet.vn
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Invest in PipelineReturn On Equity - dars.gov.et
Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SER|Serina Therapeutics Inc|Price:2.030|Chg%:-0.040 - TradingKey
Serina Therapeutics Market Sentiment - Benzinga España
Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Serina Therapeutics Inc (SER) Balance Sheet - TradingKey
Serina Therapeutics, Inc. Revenue Breakdown – AMEX:SER - TradingView
Serina Therapeutics, Inc. Revenue Breakdown – TRADEGATE:2BO - TradingView
TradingKey - TradingKey
Serina Therapeutics Inc (SER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SER|Serina Therapeutics Inc|Price:1.990|Chg%:-0.080 - TradingKey
Serina Therapeutics to present at BTIG Virtual Biotechnology Conference July 28-29, 2026 - Pluang
Serina Therapeutics, Inc. Amended CEO Employment Agreement and SEC Filing Details – July 2026 - Minichart
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - The Manila Times
Serina Sets July 29 Virtual Investor Meetings at BTIG Event - Stock Titan
Serina Therapeutics (SER) Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue PhaseEarnings Per Share - vinanet.vn
Form 4 Serina Therapeutics Inc For: 23 July By Investing.com - Investing.com Canada
Serina Therapeutics director Simon Farrell files initial beneficial ownership statement - Bitget
Director Simon Farrell awarded 30,500 options at Serina (SER) - Stock Titan
Serina Therapeutics, Inc. (SER) director Simon Farrell files Form 3 - Stock Titan
Serina Therapeutics Amends CEO Employment and Compensation Terms - TipRanks
Serina names Steve Ledger in amended CEO employment agreement - TradingView
Serina’s Parkinson’s trial doses all 8 first-cohort patients - Stock Titan
Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors - TradingView
Serina Therapeutics Adds Industry Veteran to Board - TipRanks
Serina Therapeutics appoints Farrell Simon to Board, joins Audit and Compensation Committees - TradingView
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - GlobeNewswire
Form 13D/A SERINA THERAPEUTICS For: 22 July By Investing.com - Investing.com Nigeria
Juvenescence group reports 27.3% Serina Therapeutics (SER) beneficial stake - Stock Titan
Serina Therapeutics (SER) Gains Ground: Testing Resistance at $2.28VWAP Breakout - vinanet.vn
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-than-Expected Loss as Stock Rises 7.58%Financial Data - dars.gov.et
Serina Therapeutics (SER) Q1 2026 Earnings: EPS Miss Exceeds 30% as Clinical-Stage Firm Ramps R&D SpendEPS Growth Report - vinanet.vn
SER Q1 2026 Earnings: Wider-Than-Expected Loss as Biotech Pipeline AdvancesEarnings Growth Forecast - po-news-eg.net
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Call Transcript - vinanet.vn
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Taiwan News
Serina Therapeutics director Brannan buys $2,029 in stock - Investing.com UK
Insider Buying: Stephen Brannan Acquires Shares of Serina Therap - GuruFocus
Serina Therapeutics director Brannan buys $2,029 in stock By Investing.com - Investing.com South Africa
Serina Therapeutics, Inc. Completes Sentinel Dosing In Cohort 1 Of Phase 1b Registrational Trial Of SER-252 For Advanced Parkinson?s Disease - marketscreener.com
3.04%
Capitalizzazione:
|
Volume (24 ore):